Loading company…
NextWave Pharmaceuticals developed prescription treatments for attention deficit hyperactivity disorder, including Quillivant XR.
Founded in 2005 and based in Cupertino, NextWave Pharmaceuticals developed treatments primarily for attention deficit hyperactivity disorder (ADHD). Its product portfolio included Quillivant XR®, a liquid methylphenidate medication for children aged 6 and older. Pfizer acquired the company in October 2012 for USD 255 mn, with potential additional payments of USD 425 mn tied to sales benchmarks.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in